BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 20501857)

  • 1. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.
    Duns G; van den Berg E; van Duivenbode I; Osinga J; Hollema H; Hofstra RM; Kok K
    Cancer Res; 2010 Jun; 70(11):4287-91. PubMed ID: 20501857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
    Singh RB; Amare Kadam PS
    Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma.
    Li J; Kluiver J; Osinga J; Westers H; van Werkhoven MB; Seelen MA; Sijmons RH; van den Berg A; Kok K
    Neoplasia; 2016 Jun; 18(6):339-46. PubMed ID: 27292023
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Chiang YC; Park IY; Terzo EA; Tripathi DN; Mason FM; Fahey CC; Karki M; Shuster CB; Sohn BH; Chowdhury P; Powell RT; Ohi R; Tsai YS; de Cubas AA; Khan A; Davis IJ; Strahl BD; Parker JS; Dere R; Walker CL; Rathmell WK
    Cancer Res; 2018 Jun; 78(12):3135-3146. PubMed ID: 29724720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.
    Xiang W; He J; Huang C; Chen L; Tao D; Wu X; Wang M; Luo G; Xiao X; Zeng F; Jiang G
    Oncotarget; 2015 Feb; 6(6):4066-79. PubMed ID: 25714014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
    Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
    Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.
    Li L; Miao W; Huang M; Williams P; Wang Y
    Mol Cell Proteomics; 2019 Mar; 18(3):437-447. PubMed ID: 30487242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma.
    Tiedemann RL; Hlady RA; Hanavan PD; Lake DF; Tibes R; Lee JH; Choi JH; Ho TH; Robertson KD
    Oncotarget; 2016 Jan; 7(2):1927-46. PubMed ID: 26646321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
    Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
    Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
    Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
    Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
    Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma.
    Wang L; Darling J; Zhang JS; Liu W; Qian J; Bostwick D; Hartmann L; Jenkins R; Bardenhauer W; Schutte J; Opalka B; Smith DI
    Genes Chromosomes Cancer; 2000 Jan; 27(1):1-10. PubMed ID: 10564580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis.
    Velickovic M; Delahunt B; McIver B; Grebe SK
    Mod Pathol; 2002 May; 15(5):479-85. PubMed ID: 12011252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.
    Dreijerink K; Braga E; Kuzmin I; Geil L; Duh FM; Angeloni D; Zbar B; Lerman MI; Stanbridge EJ; Minna JD; Protopopov A; Li J; Kashuba V; Klein G; Zabarovsky ER
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7504-9. PubMed ID: 11390984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
    Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
    Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
    Togo Y; Yoshikawa Y; Suzuki T; Nakano Y; Kanematsu A; Zozumi M; Nojima M; Hirota S; Yamamoto S; Hashimoto-Tamaoki T
    Int J Oncol; 2016 Apr; 48(4):1571-80. PubMed ID: 26891804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
    Ho TH; Park IY; Zhao H; Tong P; Champion MD; Yan H; Monzon FA; Hoang A; Tamboli P; Parker AS; Joseph RW; Qiao W; Dykema K; Tannir NM; Castle EP; Nunez-Nateras R; Teh BT; Wang J; Walker CL; Hung MC; Jonasch E
    Oncogene; 2016 Mar; 35(12):1565-74. PubMed ID: 26073078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
    González-Rodríguez P; Engskog-Vlachos P; Zhang H; Murgoci AN; Zerdes I; Joseph B
    Cell Death Dis; 2020 Jan; 11(1):69. PubMed ID: 31988284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.